Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer: an Multicenter, Open, Randomized, Controlled Clinical Study

NCT04195828 is registered in ClinicalTrials.gov with Fujian Medical University as lead sponsor.

NCT NCT04195828
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04195828 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer: an Multicenter, Open, Randomized, Controlled Clinical Study
Lead sponsor
Fujian Medical University
Phase
Phase 2
Overall status
Completed
Start date
June 18, 2020
Completion date
March 24, 2025
Enrollment
106 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gastric cancer